The Extraordinary Shareholders’ Meeting will be convened on third notice at a later date
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the General Meeting of Shareholders held on June 21, 2021 on second call has adopted all the ordinary resolutions presented thereto.
The shareholders taking part in the vote owned collectively 3,098,778 shares with voting rights out of the 27,697,064 shares making up the share capital and carrying voting rights. As the quorum amounted to 11.19% of the share capital, the extraordinary resolutions could not be debated.
The Extraordinary General Meeting will be adjourned, with the same agenda with respect to the extraordinary resolutions. The date of this new meeting will be announced on the Company's website. Shareholders will be able to participate in this Extraordinary Shareholders' Meeting under the same conditions as for the Shareholders' Meeting of June 21, 2021.
All the documents regarding this Extraordinary General Meeting will be available on the Company’s website as: https://www.deinove.com/en/investor-room/documentation-center/general-shareholders-meeting-preparatory-documents
Our investor relations team is available for any additional question: firstname.lastname@example.org